drugset / Trial / NCT06926829
A Long-term Trial of EB-1020 in Adult Patients With ADHD
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the double-blind trial (405-102-00112) conducted in Japan
Timeline
- Start
- 2025-06-25
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Centanafadine | Small molecule | 164.4 mg | Oral |
| Subject | Centanafadine | Small molecule | 328.8 mg | Oral |